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Abstract 
Background: Persons living with HIV (PLWH) and substance use/misuse experience significant barriers to engage-
ment in HIV care at every step of the HIV care continuum including: (1) HIV testing and diagnosis (2) linkage to clinical 
care (3) retention in care pre-antiretroviral therapy (ART) (4) ART initiation and adherence (5) viral suppression. We 
qualitatively explored the facilitators of and barriers to participation in the HIV care continuum among PLWH with 
substance use/misuse.
Methods: We performed semi-structured in-depth interviews with 34 PLWH in care with recent substance use. The 
transcripts were analyzed in an iterative process using an editing style analysis. Interviews were conducted until the-
matic saturation was achieved.
Results: Participants attributed an escalation in drug use at the time of diagnosis to denial of their disease and the 
belief that their death was inevitable and cited this as a barrier to treatment entry. In contrast, participants reported 
that experiencing adverse physical effects of uncontrolled HIV infection motivated them to enroll in care. Reported 
barriers to retention and adherence to care included forgetting medications and appointments because of drug use, 
prioritizing drug use over HIV treatment and side effects associated with medications. Participants described that pro-
gression of illness, development of a medication taking ritual and a positive provider-patient relationship all facilitated 
engagement and reengagement in care.
Conclusions: PLWH with substance use engaged in care describe barriers to and facilitators of optimal engagement 
related to and distinct from substance use. Greater understanding of the biologic, psychological and social factors 
that promote and impair engagement in care can inform interventions and reduce the increased morbidity and mor-
tality experienced by PLWH with substance use.
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Background
Substance use among persons living with HIV (PLWH) 
can result in suboptimal engagement in the HIV care 
continuum such as: delayed diagnosis and/or entry 
into care, a lower probability of initiating antiretroviral 
therapy (ART), lower rates of retention in care, and viral 
suppression [1–6].
In the United States, individuals with substance use tend 
to be diagnosed with HIV and linked to care later in their 
disease course than nondrug users [2]. Similarly, both 
active and intermittent drug use is associated with a lower 
probability of initiating ART [3, 4]. Furthermore, HIV-
infected drug users tend to have less cumulative time on 
ART and lower rates of retention in care over long periods 
of time [4, 7]. In a prospective study of 790 HIV-infected 
drug users, only 30.5 % of participants were continuously 
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retained in care over a median of 8.7 years of follow up [4]. 
This lack of engagement in care is reflected in low rates of 
viral suppression [4, 8, 9]. In an analysis of 790 injection 
drug users (IDUs) in the the AIDS linked to the intrave-
nous experience (ALIVE) study, a longitudinal study of 
IDUs in Baltimore, 53.9  % of IDUs achieved successful 
viral suppression, significantly lower than the nationally 
representative estimates of 72–77  % among the general 
population of individuals receiving HIV care [4]. In addi-
tion, a study of 1851 IDUs, found that active intermittent 
(OR 2.2, 95 % CI 1.4–2.9) and persistent drug users (OR 
1.9 CI 1.2–2.8) had a significantly higher risk of opportun-
istic infection as compared to non drug users [8].
The impact of drug use on ART adherence has been 
seen across the spectrum of drugs including alcohol, 
cocaine, stimulants and heroin [10, 11]. However, sub-
stance use does not preclude successful engagement and 
retention in care. Indeed, studies demonstrate that HIV-
infected individuals with drug use can have equal survival 
to those without drug use when prescribed and adherent 
to ART medications [12]. Therefore, understanding fac-
tors that can facilitate active participation in HIV care is 
essential in designing and implementing interventions to 
improve health care outcomes among this population.
The current literature demonstrates that substance 
use is a barrier to optimal engagement in the HIV care 
continuum. Few studies, however, have queried PLWH 
with substance use on their perceived barriers to and 
facilitators of their optimal engagement in HIV care [8, 
10, 11, 13]. To date, studies examining the relationship 
between substance use and aspects of the HIV care con-
tinuum have been largely quantitative, describing poorer 
outcomes. Qualitative research can describe complex 
aspects of health care delivery that are not effectively 
described by quantitative methods [14, 15]. Qualitative 
approaches give voice to the individuals with substance 
use, and can provide deeper insight into factors that that 
affect optimal engagement in the HIV care continuum. 
Enhancing the literature on this topic through qualitative 
work can inform the development of future epidemiolog-
ical work and practical interventions. Using semi-struc-
tured, in-depth interviews, the purpose of this study is 
to identify barriers and facilitators to engagement and 
retention in care among PLWH with substance use.
Methods
Study design, setting and participants
We performed semi-structured, in-depth interviews 
among individuals at least 18 years of age receiving care 
in an urban HIV clinic. These interviews were conducted 
between July 2013 and May 2014 as formative work for 
development of a behavioral intervention to reduce sub-
stance use among PLWH. We used purposive sampling 
recruiting individuals who were engaged in HIV care (at 
least one visit in the prior year), and who used opioids, 
cocaine, marijuana, or amphetamines in the 6  months 
prior to the interview. We deliberately chose individuals 
living with HIV with a recent past history of substance 
use. We reached out to providers to obtain referrals of 
individuals using specific drugs to ensure that we had an 
adequate range of drugs used. We also sought to recruit 
both light and heavy substance users. Specifically, we 
identified individuals in HIV treatment, as we believed 
that their stories could help inform substance use inter-
ventions delivered in HIV clinical settings.
Procedure
Upon referral to the study, written informed consent 
was obtained. Participants then underwent the NIDA 
Modified Alcohol Smoking and Substance Involvement 
Screening Test (ASSIST). The ASSIST assesses both cur-
rent and lifetime drug use of several substances including 
opioids, cocaine, marijuana, and amphetamine [16, 17]. 
Individuals reporting use of illicit substances over the 
past 6 months were eligible. No eligible participants who 
were referred refused to participate and no participant 
withdrew from the study. Participants were reimbursed 
$20.00 for their time and transportation costs.
Thirty-four, one-on-one interviews were conducted by 
either a female clinical psychologist (HH), a female physi-
cian (GC) and a male research assistant (GA) in private 
offices at the Johns Hopkins HIV Clinic. GC is a general 
internal medicine physician, with a specific focus on HIV 
and substance misuse. HH is a psychologist with a spe-
cialty in substance use, mood disorders and HIV. GA is 
a research assistant. Interviews were conducted in a pri-
vate office in the clinic.
Interviews were conducted using semi-structured 
guides, which allowed for probing and clarification [18]. 
The guide, developed by investigators GC and HH, que-
ried factors related to illicit drug use including: reasons for 
and factors influencing initiation and continuation of drug 
use; perceived pros and cons of use of specific drugs; drug 
use expectancies; triggers (internal and external); external 
influences on drug use; impact of HIV on drug use and 
conversely drug use on HIV care, including appointment 
and medication adherence; effect of drug use on doctor-
patient communication; and strategies for reduction of 
substance use. The interviews were completed in about 
60 min and were audio-recorded and transcribed verba-
tim. Identifying information was removed from interview 
transcripts. Participants were continuously enrolled until 
thematic saturation was achieved, at which point no new 
data were seen in the interviews. [19]. The institutional 
review board at the Johns Hopkins University School of 
Medicine approved the study.
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Data analysis
Interviews resulted in detailed narratives. For this project, 
we focused on how HIV infection may have affected indi-
viduals’ drug use trajectory, and how drug use may have 
affected individuals’ HIV trajectory. Qualitative analysis 
of the transcripts was done iteratively, in an editing style 
analysis. In an editing style analysis, conceptual units are 
identified in the text and used to develop themes [18, 20]. 
Data were organized in Microsoft Excel. Two investigators 
(GC and GA) independently read and coded the inter-
views. The first five interviews were read independently 
by each reviewer from the remaining interviews, and used 
to create a coding template. Each reviewer independently 
coded the remaining interviews using this template. One 
of the coders (GA) then took each independently coded 
document, compared the codes, and where there was dis-
agreement, discussed with the other coder (GC) to obtain 
consensus. The research team identified and agreed 
upon any additions to the codebook that emerged after 
the development of the initial codebook. Overall agree-
ment between the two coders was 90  %. The quality of 
our research methods was assessed against standards as 
defined in the literature [21].
Results
Clinical and demographic characteristics of the 34 par-
ticipants in this study are presented in Table 1. Nineteen 
(56 %) of the sample were men. The majority of individu-
als in this study had a history of polysubstance abuse 
(n =  25, 73.5 %) as reported on the NIDA ASSIST sur-
vey; the median NIDA ASSIST score of this sample was 
28.5, (a score of 27, indicates high risk associated with 
substance involvement) [16, 17]. Themes are discussed 
within the framework of the HIV care continuum: link-
age to care, retention in care and reengagement in care 
after periods of being lost to follow-up. Table 2 describes 
our major themes and the frequency with which these 
themes were reported.
Linkage to care
A diagnosis of HIV results in escalation of drug use 
and prevents linkage to care
Individuals perceived that their diagnosis of HIV led to 
increased drug use which prevented effective enrollment 
in care. Participants attributed this increase to 1. Denial 
at the time of diagnosis and 2. Thoughts that death from 
HIV was inevitable.
Denial and drug use to cope with an HIV diagnosis
Participants described avoidant coping, including denial 
and avoidance, and increased drug use after learning that 
they were HIV infected. Among those with experiences 
of denial, some participants expressed that drug use 
served as a reaction to the frustration and confusion 
they felt about contracting the disease. As one individ-
ual expressed: “When I first found out I was in denial 
like crazy. I wasn’t trying to hear it, you know, because 
I’m saying how can I, how could it be, me… I used more 
often, it’s like the ball rolling down the hill again. It was 
like that’s all I lived for was to get high” (Female, age 47).
For many participants, taking medication and engag-
ing in care would be admitting that the diagnosis was a 
reality. By contrast, drug use allowed for the avoidance 
of these issues. One participant increased her drug use 
after her diagnosis due to denial of her diagnosis. She 
associated these feelings of denial to her lack of partici-
pation in care. “I went on a thing where I was like I really 
did want to think I had it, maybe it would go away …I 
didn’t even want to [go to the doctor] because I didn’t 
even want to believe I had it for one thing… You know, 
I just didn’t want to really believe it. Then… it took me a 
while to even start it taking my medicine right” (Female, 
age 51).





 Female 15 (44.1)
 Male 19 (55.9)
Race
 African American 30 (88.2)
 White 4 (22.8)
Drug use (lifetime)
 Polysubstance use 33 (97.1)
 Single substance use 1 (2.9)
Drug use (past 3 months)
 No substance use 8 (23.5)
 Single substance use 1 (2.9)
 Poly substance use 25 (73.5)
 Marijuana 21 (61.8)
 Cocaine 17 (50.0)
 Heroin 10 (29.4)
 Methamphetamines 2 (5.9)
Injection drug use
 Never 14 (41.2)
 Yes, but not in past 3 months 14 (41.2)
 Yes 6 (17.6)
ASSIST substance involvement score, median 28.5
% Taking ART 88.3 %
Undetectable viral load (HIV-RNA < 400) 88.3 %
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Escalation in drug use due to belief that death due to HIV is 
inevitable
Other individuals experienced a period of increased drug 
use post-diagnosis due to the belief that their death from 
HIV was inevitable. As one person explained, “For me, 
I actually tried to run away again and I didn’t see [my 
doctor] for a while. I ran back into the streets because I 
found out, oh I had the bug of life, you know, my death is 
coming soon and everything. I wanted to escape” (Male, 
age 33).
Some participants relapsed into drug use after peri-
ods of sobriety immediately after their diagnosis. One 
individual, who was abstinent from drugs at the time of 
diagnosis, stated: “from that point on, I think I wanted 
to use drugs again” (Female, age 61). Individuals related 
this fatalistic attitude about their prognosis to a lack of 
knowledge about the disease. One participant explained: 
“I was in denial when I found out. I started using even 
more… when I went back I started using again and at that 
point I never took medication for the HIV… I was really 
Table 2 Themes and  subthemes that  addressed barriers to  and facilitators of  engagement in  care for  HIV+  substance 
users




 Barriers to linkage to care
  Denial of HIV diagnosis 8 “When I first found out, I was in denial like crazy. I wasn’t trying to hear 
it, you know, because I’m saying how can I, how could it be me….Yes, 
I used more often, it’s like that’s all I lived for was to get high”—female, 
age 47
  Inevitability of death from HIV 11 “For me, I actually tried to run away again and I didn’t see [my doctor] 
for a while. I ran back into the streets because I found out, oh I had 
the bug of life, you know, my death is coming soon and everything. I 
wanted to escape, I ran away from home again…It did nothing for me, 
the shit was in me, it’s going to take me eventually”—male, age 33
 Facilitators of linkage to care
  Illness/disease progression 8 “…they told me what my CD4 count was. And they said I was AIDS 
defined. And the doctor asked me did I want to die. I told him, no, I 
didn’t want to die… And that’s when I decided to get on the meds. 
From them telling me that I could die from it”—male, age 55
Retention in care
 Prioritization of drug use over HIV treatment 13 “When I drugged I ain’t gonna take my medicine right… I don’t want 
to do anything but get high. The way I was using, when I use, I would 
use”—female, age 51
 Forgetting to take medication 10 “… when I’m high, I’ll forget. That’s put as simple as I can… I’m chasing 
the drug. I’m not thinking about my health.”—male, age 28
 Side effects of medication 6 “…He would give me the medicine but I wouldn’t take it. And I was 
thinking like I knew a lot of people that had HIV too… when they 
wasn’t taking the medicine, they was fine, but as soon as they started 
taking the medicine, like they were dying like flies. So I figured I ain’t 
taking that medicine. I ain’t messing with that.”—female, age 42
Reengagement in care
 Illness/disease progression 8 “…, but I tried my best in spite of that to stay somewhat compliant with 
those pills, you know. I didn’t want to get sick, so I took them”—male, 
age 48
 Ritual associated with medication 9 “At one point it used to make miss doses because I would be getting 
high. You know if I’m getting high, I wouldn’t think about taking my 
medication but now, you know, it’s like a program. Every time I eat a 
meal in the daytime and the evening time, I take my medication along 
with my meal so. As long as I eat two meals a day, I’m going to take my 
medication”—male, age 59
 Positive provider-patient relationship 15 “… if there was something that she didn’t like that I’ve done, as far as 
taking my medication, she would argue with me and I wouldn’t have 
no problem with her doing that because she was right and I was 
wrong. That made me feel like she cared. So that’s how it was with 
me”—female, age 54
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trying to destroy myself… I immediately thought it was a 
death sentence. You know, I didn’t get educated on any-
thing. I started using even more” (Female, age 47).
Another participant agreed, stating that after his diag-
nosis:“… it was a real [messed] up day. And I started get-
ting’ [messed] up after that day. … It increased 300  % 
[drug use] … Because I thought I was gonna be dead in 
a year and I said, what the [heck], get high. I was workin’ 
goin’ to school and everything, I had a career and a nice 
job, nice home, nice car, nice clothes, and everything. 
It all went up in smoke in a year, I didn’t care… I’m not 
gonna be here long. So get high, get high, get high, And 
that’s what I did for a year” (Male, age 53).
Beliefs about HIV infection as a rapidly terminal dis-
ease, and denial and avoidance of accepting this diag-
nosis led to escalation in drug use as a means of coping. 
This reaction to HIV diagnosis subsequently resulted in 
delayed linkage to care.
Adverse symptoms of HIV infection motivated enrollment 
in care
After diagnosis, individuals expressed that they were 
more likely to enroll in care once they experienced the 
adverse effects of an untreated HIV infection. When 
asked what motivated her to start taking medication after 
10 years of being treatment naïve, one participant stated, 
“What changed my mind is how many times I started to 
get sick. …All during that 10  years, I was sick. I’ve had 
shingles. I’ve had TB. I’ve had pneumonia. I had a lot of 
stuff. So when I finally got here [to the clinic] … I was 
sick. I was close to dying and you know, and [the doctor] 
just worked with me. I finally decided to take the medi-
cine and ever since then, I’ve been fine since and I take 
my medicine every day…I make all my doctor’s appoint-
ments” (Female, age 46).
Similarly, one man engaged in care after he was con-
fronted with his prognosis without treatment. He states: 
“I was sick. I went to the emergency room and they ran a 
series of tests and they found out–they told me what my 
CD4 count was. And they said I was AIDS defined. And 
the doctor asked me did I want to die. I told him, no, I 
didn’t want to die. And that’s when the doctor explained 
to me that I needed to get on HIV meds or surely I was 
going to die. And that’s when I decided to get on the 
meds. From them telling me that I could die from it” 
(Male, age 55).
Retention in care
Prioritization of drug use prevents ART and appointment 
adherence
Once participants were initially linked to care, they 
often faced difficulties successfully being retained in 
care, as defined by adherence to ART and appointments. 
Individuals, consumed by their drug use, neglected their 
medical care. Conscious prioritization of drug use over 
HIV treatment directly hindered both appointment and 
ART adherence. Indirectly, forgetting to take medication 
as a result of drug use prevented ART adherence.
Participants vividly described how their use impaired 
the ability to seek HIV care.
“… I didn’t make a lot of appointments. I wasn’t keep-
ing doctor’s appointments. It’s like I just didn’t care… 
Because I was out all day and all night running and chas-
ing and I wasn’t thinking about doctors. I wasn’t thinking 
about my health. I’ve been thinking about none of that, so 
yeah” (Female, age 42). For these participants, drug use 
superseded the need for medical care.
In addition to appointment adherence, individuals 
explained that ART was quickly forgotten once individu-
als started using drugs. One participant explained: “You 
going to forget because you running or chasing, or it’s 
just that you just don’t… F-the pills” (Female, age 41). 
Another participant succinctly summarized the effect 
drugs had on his engagement in care: “…when I’m high 
I’ll forget. That’s put as simple as I can…I’m chasing the 
drug. I’m not thinking about my health…So I wake up. I 
feel all right. I’m out the door. Then I realize I didn’t take 
my meds… [and then] I stay out ‘til I go back home and 
take them then” (Male, age 48).
This suboptimal adherence to ART was not only due 
to forgetting to take medication but also, a clear prior-
itization of drug use over HIV care. As one participant 
relates:“When I drugged I ain’t gonna take my medicine 
right… I don’t want to do nothing but get high. The way 
I was using, when I would use, I would use” (Female, age 
51).
Other participants would not take their HIV medica-
tion because of the fear that the medication would inter-
fere with the full effect of the high. One man explained 
“… when I knew that I was getting ready to relapse, I just 
stopped taking everything… I didn’t want the drugs to 
get in the way of me feeling the high” (Male, age 53).
Participants’ descriptions of their adherence while in 
the midst of active substance use, illuminate powerful 
and all consuming effect drugs can have in their lives.
Fear of adverse side effects of ART prevents adherence
Unrelated to substance use, participants described that 
they failed to adhere to ART because of the potential the 
adverse effects of these medications, both rumored and 
experienced. As one participant expressed, “[The doctor] 
would give me the medicine but I wouldn’t take it. And 
I was thinking like I knew a lot of people that had HIV 
too and […] when they wasn’t taking the medicine, they 
was fine, but as soon as they started taking the medicine, 
like they were dying like flies. So I figured I ain’t taking 
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that medicine. I ain’t messing with that” (Female, age 42). 
Similarly, another individual had heard “…about people 
taking medication for it and they would be still sick, you 
know, so it was a lot of things that I didn’t know about…
I heard things about the cocktails and how they would 
make them extremely sick, throwing up constantly, just 
where the regimen wasn’t working” (Female, age 47). 
Fearful of the rumored adverse effects of ART, individuals 
failed to either initiate or adhere to medication regimens.
In contrast, one woman avoided taking medications 
because of how they would change her physical appear-
ance, and consequently other’s perception of her. She 
states that she “didn’t get on medication for years… 
because I was scared of how it would make me look. 
The people that I would see that were on AZT and dif-
ferent medications, they started looking like they were 
half-dead. You know, looked like they were ashy, black 
looking, hair started falling out, stuff like that … [I was 
worried about] how it would make me look and I didn’t 
want to tell anybody” (Female, age 50). The stigma of HIV 
infection and its treatment was enough to prevent adher-
ence to medications.
Others stopped taking medications after experiencing 
significant side effects that severely impacted their qual-
ity of life. One participant explains “But I wasn’t takin’ 
no medicine. I would get the prescriptions, I might take 
it for a week, then I didn’t. They make me feel terrible, 
you know what I mean… Cause I’m not the same, I can’t 
do what I wanna do, I don’t work anymore, it takes me a 
week to clean up the bedroom and the bathroom, takes 
me two or three days to do it, but I get outta breath, I 
gotta sit down and so I said, f-it, I might as well get high” 
(Male, age 53).
When individuals reflected on factors that challenged 
their engagement in care, they identified factors appli-
cable to the general HIV population at large, in addition 
to those related to drug use. While prioritization of drug 
use over HIV care negatively impacted adherence, fears 
and misconceptions about medication side effects and 
stigma surrounding the act of taking these medications 
also hindered adherence to care.
Reengagement in care
Symptoms of untreated HIV infection motivated 
reengagement in care
Participants expressed that illness, or the feeling that 
one’s health was deteriorating, motivated them to reen-
gage in both medication and appointment adherence 
after periods of being lost to follow up. The realization 
that their lives were actually in danger motivated patients 
to take control of their medical care. As one participant 
explains: “And they was like ‘Your cells are’ my cells was 
down to 27… yeah my CD4 count was down to 27. And 
she says ‘You know you’re full blown with AIDS now’ I 
said Oh hell, no. I need meds. I said I’m going to take it. I 
promise, I’m going to take it. So what they did, they made 
me come up here everyday” (Female, age 41). Another 
participant started adhering to medications “…because 
my count got real low. That’s when I started taking it and 
trying to do the right thing” (Female, age 51). Fear of ill-
ness often promoted medication adherence even dur-
ing periods of active drug use. As one man explains, “Of 
course it wasn’t always six hours if I’m partying during 
everything too, but I tried my best in spite of that to stay 
somewhat compliant with those pills, you know. I didn’t 
want to get sick, so I took them” (Male, age 48).
Structure or ritual enabled effective medication adherence
Individuals perceived that establishing a ritual or struc-
ture around taking medications allowed for successful 
reengagement and retention in care. When patients were 
taking multiple medications, having a clear organiza-
tional strategy helped ease adherence to complex treat-
ment regimens. For example, one participant depended 
on a pillbox to organize her complex medication plan. As 
she explained, “…it works for me…this is a ritual I do to 
make me on Sundays, do my medicine. Then I just pour 
them out on the week for two weeks, and when I know 
I’m running out, I redo them again” (Female, age 50). 
Taking medications at the same time everyday prevented 
patients from missing doses. As one individual described: 
“When I wake up I have habits and my habits, when I get 
up, the first thing I do is grab my pills and I plug up the 
coffee pot and I take my pills so. Before I even smoke a 
cigarette I’m taking my medicine, yeah” (Female, age 47).
Adopting medication into one’s daily routine pro-
moted effective adherence even during periods of drug 
use. One participant explained how creating a ritual 
changed the way that drug use influenced his ability to 
take medication.
“At one point [drug use] used to make miss doses 
because I would be getting high. You know if I’m getting 
high, I wouldn’t think about taking my medication but 
now, you know, it’s like a program. Every time I eat a meal 
in the daytime and the evening time, I take my medica-
tion along with my meal so. As long as I eat two meals a 
day, I’m going to take my medication. If for some reason 
I miss a meal because I’m using that’s the very small per-
centage of the time that I would miss my medication but 
most of the time, even before I start using, I’ll make sure 
I take my–because I always take first–my morning dose” 
(Male, age 59).
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Positive provider‑patient relationships empowered 
individuals to participate in care
The provider-patient relationship plays a key role in 
maintaining medication and appointment adherence, 
especially after period of being lost to follow-up, thus 
contributing to successful reengagement in care. Individ-
uals also expressed that satisfaction with their provider 
relationship positively impacted their desire to engage 
in care, to be truthful with their provider and to comply 
with treatment standards. Participants preferred provid-
ers that they described as “caring” and “open-minded”. 
Furthermore, participants were more likely to engage 
in care when they had providers who listened to their 
patient’s stories and explained the details of the disease 
and the treatment plan.
Many participants appreciated when their providers 
became upset with them when they did not follow treat-
ment protocols because they viewed this reaction as a 
sign that their physician truly cared about their wellbe-
ing. As one participant relays “… if there was something 
that she didn’t like that I’ve done, as far as taking my 
medication, she would argue with me and I wouldn’t have 
no problem with her doing that because she was right 
and I was wrong. That made me feel like she cared. So 
that’s how it was with me” (Female, age 54). The percep-
tion that their providers were invested in their health 
fostered a reciprocal relationship in which the patients 
became accountable for adhering to care.
In contrast, patients tended to disengage in care when 
they felt judged by their provider for their drug use or 
their HIV status. One individual believed that her sub-
stance use history negatively influenced the way her pro-
viders treated her. She explained: “A lotta times when 
you talk to a provider, and soon as they find out you’re an 
addict, everything, their whole demeanor changes. And 
I’ve had that done. Once you tell ‘em–if you tell ‘em you 
have a pain or ailment, the first thing they swear, you’re 
tryin to get drugs… they need to stop stereotypin’ their 
patients because of an addiction. It’s crazy, that makes 
people not wanna go to hospitals and don’t wanna see 
their doctors or anything else. And if somethin’ is wrong 
with them it makes them leery on sayin something about 
it because of the way they gonna be looked at” (Female, 
age 45).
Fear of illness, the establishment of a medication ritual 
and a positive doctor-patient relationship all motivated 
individuals to reinitiate and be retained in care during 
periods of both sobriety and substance use. These factors 
increased participants’ engagement in the care cascade 
resulting in improved HIV outcomes.
Discussion
At an urban HIV clinic, we used qualitative interviewing 
to explore the barriers to and facilitators of engagement 
in care among 34 individuals with a history of substance 
use. From these interviews, themes related to the HIV 
care continuum emerged. The themes, reflecting link-
age to care, retention in care and reengagement in care, 
characterized the participants’ relationship with the care 
continuum.
At the time of HIV diagnosis, participants described 
an escalation in drug use. Some individuals associated 
this behavior with feelings that death from HIV would 
be inevitable while others associated this increased drug 
use with feelings of denial about their disease. Theories 
of psychological adjustment suggest that an individual’s 
perspective on his or her disease process significantly 
impacts coping and adjustment to the disease [22]. Cop-
ing with chronic disease can involve approaching or 
avoiding demands of disease. In particular, avoidance is 
associated with cognitive and behavioral responses such 
as denial, suppression and disengagement [23]. Perceived 
threat to life goals and lack of disease-related self efficacy 
have been identified as key determinants of adjustment 
and have been associated with psychological pain and 
distress. For our participants, the diagnosis of HIV and 
its potential consequences resulted in significant psy-
chological stress and maladaptive adjustment strategies. 
Drug use in particular may play a role in avoidance cop-
ing by diverting attention away from HIV diagnosis [22].
The experience of being diagnosed with a chronic ill-
ness such as HIV can either promote enrollment or 
engagement in care or can cause significant psychologi-
cal stress and avoidant coping behaviors that can hin-
der linkage to care [24, 25]. The detrimental effect this 
experience has on enrollment in care can be exacerbated 
among already stigmatized populations. Among people 
who use drugs, increased psychological stress, due to any 
cause, can also lead to destructive behaviors and greater 
addiction vulnerability [26–28]. Our analysis suggests 
that this psychological stress manifests itself in increased 
drug use due to feelings of denial or inevitability of death 
associated with disease. Consequently, this phenomenon 
can prevent appropriate enrollment in care.
Case management interventions at the time of, and 
the period after diagnosis can help improve the likeli-
hood that patients are linked to and retained in care 
[29, 30]. Current guidelines suggest that multiple case-
management contacts for newly diagnosed individuals 
as well as intensive outreach for individuals not engaged 
in care within 6  months of diagnosis can help prevent 
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individuals recently diagnosed with HIV from being lost 
to follow up [31, 32]. At the time of diagnosis, interven-
tions should involve patient-centered communication in 
order to minimize any adverse outcomes associated with 
the experience of diagnosis. This type of intervention has 
been demonstrated to be effective in communicating the 
diagnoses of other diseases, such as cancer. In a cross-
sectional study of Australian patients with melanoma, 
effective and conscientious communication of difficult 
diagnoses was associated with lower risk of anxiety and 
depression among patients [33]. As described in the can-
cer literature, patients’ preferred communication styles 
included focus on content (information about the dis-
ease), facilitation (setting and context of disclosure) and 
support [34, 35]. Intensive, repeated interventions at time 
of HIV diagnosis may be important to reduce morbid-
ity and mortality among individuals with HIV and sub-
stance use, and decrease transmission risk through early 
engagement in care.
Participants identified barriers to optimal use of ART 
including (1) forgetting to take medications during peri-
ods of drug use, (2) prioritization of drug use over HIV 
medications and (3) adverse side effects of medications. 
Prioritization of substance use, over HIV medications has 
been described in the literature [36]. In a twelve-month 
prospective study of people who were on ART and used 
alcohol, participants missed doses or stopped medication 
altogether when using alcohol. Some individuals associ-
ated this behavior with beliefs that mixing ART and alco-
hol was dangerous. Others endorsed skipping medication 
doses because of beliefs that alcohol diminished the 
effectiveness of HIV medications, indicating a prioritiza-
tion of substance use over treatment [37]. These beliefs 
are very similar to those expressed by our participants, 
reinforcing the importance of examining patients’ beliefs 
about interactions between ART and drugs when assess-
ing their adherence to medications.
These barriers are not completely distinct from adher-
ence barriers identified by nonsubstance using popula-
tions. A quantitative study of HIV-infected individuals in 
New York City identified forgetting appointments as one 
of the most common reasons for missing appointments. 
Our qualitative analysis corroborates this, and also sug-
gests that missing appointments is associated with a 
conscious prioritization of drug use over HIV care [38]. 
Nonadherence to ART is attributed to a variety of struc-
tural, behavioral, and psychosocial factors amongst the 
nonsubstance using PLWH as well as the subpopulation 
of substance users.
Our analysis also identified facilitators to care that 
were similar to general HIV-infected population. Specifi-
cally, experiencing symptoms of untreated HIV infection 
motivated people to engage in care [39]. Furthermore, 
establishing a ritual or behavior pattern surrounding 
medication improved ART adherence [40]. In a meta-
analysis of barriers and facilitators to ART adherence, 
patients reported that incorporating ART into daily 
routines and the use of reminder tools both helped 
improve medication adherence [39]. Evidence support-
ing educational counseling (brief medication adherence 
psychoeducational counseling sessions with multi-com-
partment weekly pill organizers) demonstrated a signifi-
cant increase in medication and appointment adherence 
[38]. Though more research is needed on this topic, inte-
grated programs that focus on integrated medication 
and behavioral therapy (including cognitive behavioral 
therapy, motivational interviewing) may be effective in 
improving treatment adherence [41]. Directly observed 
therapy has increased medication adherence and viral 
load suppression among substance users [42, 43]. In addi-
tion, studies suggest that social support plays a significant 
role in facilitating ART adherence [44].
The quality of the provider-patient relationship also 
impacts participation in HIV care. Emotionally sup-
portive relationships have been associated with positive 
adjustment to chronic disease [22]. PLWH who per-
ceived their primary care providers as empathetic, and 
knowledgeable about HIV expressed higher rates of sat-
isfaction with their providers and higher rates of adher-
ence to ART [45–47]. These individuals also reported 
that they felt comfortable speaking with their providers 
about personal issues [45]. A positive provider-patient 
relationship also significantly influenced engagement in 
care among HIV-infected substance users. A prospec-
tive study focused on medication adherence amongst 
injection drug users found that those who reported a 
positive provider-patient relationship had 45  % greater 
odds of ART use 6  months later  [48]. Similarly, injec-
tion drug users who reported a positive relationship with 
their providers were significantly more likely to have an 
undetectable viral load. Of interest, participants associ-
ated episodes in which their providers became upset or 
frustrated at them over their lack of engagement in care 
as examples that their providers truly were invested in 
their care. This belief motivated individuals to be more 
accountable in their participation in the care continuum. 
Individuals were also motivated to adhere to care when 
their providers confronted them with potential conse-
quences of their noncompliance with medical care. These 
findings contradict the non-confrontational approaches 
generally recommended in the literature, suggesting the 
need for further investigation [49, 50].
Conversely, negative provider-patient relationships can 
hinder engagement in the HIV care continuum, includ-
ing initiation and adherence to ART. Illicit drug users 
treated by physicians with negative attitudes towards 
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drug users tended to have later exposure to ART. Phy-
sicians may hesitate to prescribe ART to HIV-infected 
drug users because of the belief that these individuals will 
not adhere to treatment plans and that misuse of medica-
tion will lead to drug resistance [5]. This misperception 
can lead to increased morbidity and mortality amongst 
this population as well as increased risk of HIV trans-
mission. Additionally, some studies suggest that provider 
emphasis on drug-related barriers to care and lack of 
emphasis on non-drug related barriers influences dispari-
ties in care amongst this population [38]. With appropri-
ate structural and social supports, these individuals can 
achieve effective adherence [51, 52]. Directly adminis-
tered antiretroviral therapy, medication assisted therapy, 
and multi-component nurse directed interventions all 
improved short-term adherence and virologic outcomes 
among HIV-infected individuals who use drugs [41].
This study has limitations. All of the individuals were 
recruited from one clinic. The majority of participants 
had a significant lifetime history of polysubstance use 
and reported substance use within the last 3  months 
prior to this study. Of note, these participants had var-
ied levels of risk associated with substance use as defined 
by ASSIST scores. Nonetheless, the majority of partici-
pants in this study were adherent to ART and achieved 
viral suppression, reflecting successful engagement in 
the HIV care continuum. This characteristic of the study 
population may limit the transferability of our findings to 
those engaged in care; however, there are likely themes 
that transfer to other individuals with less severe sub-
stance use or use of a single substance; such as the utility 
of establishing a ritual for taking medications. Partici-
pants reflected upon their personal history of substance 
use and experiences with HIV to identify the barriers and 
facilitators that emerged as themes. As a result, we must 
consider recall bias as a potential limitation of this study. 
However, retrospective information gleaned from par-
ticipants related to initial coping with receipt of a diag-
nosis, including denial, and escalation of drug use, may 
be applicable to those not engaged in care as yet, and 
provides insight into the types of support individuals may 
need at the time of diagnosis. Additionally, as is intrinsic 
to qualitative research, the interviewers may have indi-
rectly affected the content of the interviews.
Our study provides deeper insight into the barriers and 
facilitators to care among PLWH who use drugs, spe-
cifically within the context of the HIV care continuum. 
Substance use can lead to increased HIV morbidity and 
mortality as well as increased risk of HIV transmission 
[53]. Therefore, lack of engagement in care for individuals 
who use drugs can have serious consequences for both 
individuals as well as the general population. While peo-
ple who use drugs are often considered a distinct group 
within the HIV-infected population and thus have unique 
factors that influence their care, through our analysis, 
we also identified many barriers and facilitators to care 
that were similar to PLWH without a history of substance 
misuse. Our findings suggest the need for interventions 
that can improve participation in care at every step of the 
care continuum. Despite effective ART, engagement in 
the HIV care continuum remains suboptimal, resulting 
in increased morbidity, mortality, and disease transmis-
sion [54, 55]. Identifying these individuals and developing 
interventions to improve engagement in care is an essen-
tial part of reducing the burden of HIV infection.
Conclusions
This study identified many barriers and facilitators to 
participation in care amongst HIV-infected individuals 
with substance use/misuse. After diagnosis, increased 
drug use hindered effective enrollment in care while ill-
ness motivated individuals to engage in care. Forgetting 
to take medications, prioritization of drug use over HIV 
care and adverse side effects of medications emerged as 
barriers to retention in care. Illness, ritual associated with 
medications and a positive provider-patient relation-
ship served as facilitators to reengagement in care. These 
identified barriers and facilitators to engagement in HIV 
care can inform interventions to improve participation in 
care and thus reduce the morbidity and mortality asso-
ciated with HIV infection amongst individuals who use 
drugs.
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